Immune microenvironment associated with the severity of Langerhans cell histiocytosis in children

Cai, Fengqing; Peng, Zhaoyang; Xu, Hui; Gao, Hui; Liao, Chan; Xu, Xiaojun; Guo, Xiaoping; Gu, Weizhong; Zhu, Kun; Shu, Qiang; Shen, Hongqiang

doi:10.1016/j.cyto.2023.156378

Cited by 3 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These in ltrating cells produce large amounts of proin ammatory cytokines and chemokines, creating a lesional cytokine storm [9,10]. Several studies have shown that increased serum cytokine and chemokines, such as IL-6, IL-10, IL-18, TNF-α, et al, were associated with the disease extent or the mutation status in LCH [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

Zhao,

Lian,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm with inflammatory characteristics. This study aims to investigate the correlation between sCD25 levels and clinical characteristics and prognosis in pediatric LCH. Methods Serum sCD25 levels were measured in 370 LCH patients under 18 years old using ELISA assays. The patients were divided into two cohorts based on different treatment regiments. We further assessed the predictive value for prognosis impact of sCD25 in a test cohort, which was validated in the independent validation cohort. Results The median serum sCD25 level at diagnosis was 3908 pg/ml (range: 231 − 44 000). sCD25 level was significantly higher in MS RO + LCH patients compared to SS LCH patients (P < 0.001). Patients with increased sCD25 were more likely have involvement of risk organs, skin, lung, lymph node, or pituitary (all P < 0.05). sCD25 level could predict LCH progression and relapse with an area under the ROC curve of 60.6%. The best cutoff value was determined at 2921 pg/ml. High-sCD25 group had a significantly worse progression-free survival than those in the low-sCD25 group (P < 0.05). Conclusion Elevated serum sCD25 levels at initial diagnosis was associated with high-risk clinical features and worse prognosis. sCD25 levels can predict the progression/recurrence of LCH after treatment with first-line chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

Zhao,

Lian,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…These infiltrating cells produce large amounts of pro-inflammatory cytokines and chemokines, creating a lesional cytokine storm 9,10 . Several studies have shown that increased serum cytokine and chemokines, such as IL-6, IL-10, IL-18, TNF-α, et al, were associated with the disease extent or the mutation status in LCH [11][12][13] . Soluble CD25 (sCD25), a soluble form of the α-subunit of interleukin-2 receptor (IL-2Rα), is generated exclusively by the proteolytic cleavage of the membrane-bound IL-2Rα, and its concentration is thought to reflect the immune activation during infection or inflammation [14][15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

Zhao,

Lian,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm with inflammatory characteristics. This study aims to investigate the correlation between sCD25 levels and clinical characteristics and prognosis in pediatric LCH. Procedure: Serum sCD25 levels were measured in 370 LCH patients under 18 years old using ELISA assays. The patients were divided into two cohorts based on different treatment regiments. We further assessed the predictive value for prognosis impact of sCD25 in a test cohort, which was validated in the independent validation cohort. Results: The median serum sCD25 level at diagnosis was 3908 pg/ml (range: 231-44 000). sCD25 level was significantly higher in MS RO+ LCH patients compared to SS LCH patients ( P<0.001). Patients with increased sCD25 were more likely have involvement of risk organs, skin, lung, lymph node, or pituitary (all P < 0.05). sCD25 level could predict LCH progression and relapse with an area under the ROC curve of 60.6%. The best cutoff value was determined at 2921 pg/ml. High-sCD25 group had a significantly worse progression-free survival than those in the low-sCD25 group ( P < 0.05). Conclusion: Elevated serum sCD25 levels at initial diagnosis was associated with high-risk clinical features and worse prognosis. sCD25 levels can predict the progression/recurrence of LCH after treatment with first-line chemotherapy.

show abstract

The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis

Zhao,

Lian,

et al. 2024

Jornal de Pediatria

View full text Add to dashboard Cite

Immune microenvironment associated with the severity of Langerhans cell histiocytosis in children

Cited by 3 publications

References 40 publications

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis

Contact Info

Product

Resources

About